NCT06018506View on ClinicalTrials.gov

A Phase I Study of BR108 in Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

October 21, 2024

Study Completion Date

March 2, 2026

Conditions
Hematologic Malignancy
Interventions
DRUG

BR108 injection

Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY